A recent Cardiology digest,
as sent to subscribers

Study Type: RCT (prespecified subgroup analysis of VESALIUS-CV trial)

Key Question: Does baseline lipoprotein(a) level identify patients without prior MI/stroke who derive greater cardiovascular benefit from evolocumab therapy?

Key Findings:

• Higher baseline Lp(a) independently increased major coronary event risk by 15% per 100 nmol/L increase (HR 1.15, 95%CI 1.05-1.26), particularly for MI (HR 1.23)
• Evolocumab achieved similar relative risk reductions regardless of baseline Lp(a): 41% in high Lp(a) (>105 nmol/L) vs 35% in low Lp(a) groups
• Greater absolute benefit in high Lp(a) patients: NNT 28 vs 40 to prevent one major coronary event over 5 years

Clinical Relevance: Supports using elevated Lp(a) to identify primary prevention patients who may derive greater absolute cardiovascular benefit from PCSK9 inhibitor therapy, relevant for NHS resource allocation decisions.

Limitations: Subgroup analysis with potential for unmeasured confounding and limited power for interaction testing.

Study Type: Experimental study using cell culture, animal models, and human tissue specimens

Key Question: How does the transcription factor BACH1 contribute to pulmonary vascular remodeling and pulmonary hypertension development?

Key Findings:

• BACH1 is upregulated in lung tissues from patients with idiopathic PAH and experimental PH models
• Hypoxia stabilises BACH1 protein by reducing PHD2-mediated degradation, leading to BACH1 accumulation in pulmonary artery smooth muscle cells
• BACH1 directly activates TGFBR2 transcription, promoting SMAD signaling and extracellular matrix deposition; TGFBR2 kinase inhibition attenuated BACH1-induced PH development

Clinical Relevance: This research identifies BACH1 as a potential therapeutic target for pulmonary hypertension, particularly relevant given the limited treatment options currently available through NHS specialist PH centres.

Limitations: Findings are primarily from experimental models with limited validation in human PAH tissue specimens.

Study Type: Single-blind, sham-controlled randomized clinical trial

Key Question: Does pulsed field ablation provide genuine clinical benefit beyond placebo effects for symptomatic atrial fibrillation patients?

Key Findings:

• AF recurrence at 6 months: 6.7% with PFA vs 83.3% with sham procedure (hazard ratio 19.6, 95% CI 6.7-76.9)
• Quality of life scores improved significantly more with PFA (+43.9 points) compared to sham (+11.3 points), difference 32.6 points (95% CI 20.2-44.9)
• AF burden and anxiety/depression scores were significantly reduced with PFA versus sham

Clinical Relevance: This provides robust evidence that catheter ablation benefits extend beyond placebo effects, addressing longstanding concerns about subjective outcomes in AF ablation trials relevant to UK practice guidelines.

Limitations: Small sample size (n=60) limits generalisability and precision of effect estimates.

Study Type: Retrospective biobank analysis

Key Question: Do variants of uncertain significance (VUS) enriched in individuals of African ancestry confer measurable cardiovascular risk for cardiomyopathy and arrhythmias?

Key Findings:

• Among 82 ancestry-enriched VUS in 96,897 individuals, PKP2 p.Val558Ile increased ventricular arrhythmia/sudden cardiac death risk 4-fold (aOR 4.02, 95% CI 1.85-8.71)
• ELAC2 p.Ile396Val was associated with heart failure (aOR 1.67) and atrial arrhythmias (aOR 1.88); FLNC p.Gly11Ser and PKP2 p.Val842Ile increased heart failure risk approximately 2-fold
• PKP2 p.Val558Ile met criteria for likely pathogenic reclassification, potentially affecting an estimated 24,000 Black adults in the US

Clinical Relevance: This addresses health inequity in genetic testing for inherited cardiac conditions, providing evidence to reclassify VUS variants that predominantly affect patients of African ancestry in UK cardiology practice.

Limitations: Retrospective biobank design cannot establish causality and may be subject to ascertainment bias.

Study Type: Single-cell and spatial transcriptomic analysis of human cardiac tissue

Key Question: What are the molecular mechanisms underlying the distinct histopathological regions and disease progression in cardiac sarcoidosis?

Key Findings:

• Three distinct cardiac regions showed different cellular compositions: preserved myocardium with chemoattractant-expressing cardiomyocytes/fibroblasts, granulomatous areas with fusion-promoting macrophages and Th17 cells, and fibrotic regions with tertiary lymphoid structures
• Clonally expanded B cells produced autoantibodies against periplakin (PPL), a desmosome protein, rather than microbial antigens
• Cardiomyocytes upregulated arrhythmogenic genes and inflammasome pathways associated with cell death

Clinical Relevance: This identifies cardiac sarcoidosis as an autoimmune disorder with specific therapeutic targets (B-cell pathways, granuloma formation) and explains shared features with arrhythmogenic cardiomyopathies through desmosome autoimmunity.

Limitations: Single study using post-mortem or explanted tissue may not reflect earlier disease stages or treatment responses.

Study Type: Scientific statement/expert consensus

Key Question: What ethical principles should guide heart transplant allocation policy as the system evolves beyond the traditional "sickest first" approach?

Key Findings:

• Current "sickest patients first" allocation principle requires reassessment given increasing organ demand and technological advances
• Clinicians face ethical tension between individual patient advocacy and equitable population-level allocation policies
• Future allocation systems need foundational ethical frameworks addressing fairness, stewardship, and responsible resource distribution

Clinical Relevance: UK transplant cardiologists must understand evolving ethical frameworks as NHS organ allocation policies adapt to similar pressures of organ scarcity and advancing mechanical support technologies.

Limitations: This is a position statement rather than empirical research, providing guidance principles without data-driven recommendations.

Study Type: Experimental study using mouse models with human biomarker validation

Key Question: Does bisphenol F (BPF) exposure cause cardiovascular injury through gut microbiota-mediated metabolic pathways?

Key Findings:

• BPF detected in 90.5% of human urine samples and caused cardiomyocyte hypertrophy and cardiac dysfunction in mice through gut microbiota-dependent mechanisms
• Gut bacteria convert BPF to N-acetylputrescine (NAP) via the Sat1 enzyme pathway, which damages intestinal barriers and activates cardiac p53 pathways leading to hypertrophy
• Akkermansia muciniphila supplementation mitigated cardiac and intestinal injury by downregulating the Sat1-NAP axis

Clinical Relevance: Given widespread BPF exposure in plastics, this gut-heart axis mechanism could represent an underrecognised contributor to heart failure development, potentially relevant for environmental cardiology assessment in NHS practice.

Limitations: Mouse model findings may not directly translate to human cardiovascular disease given species differences in metabolism and gut microbiota composition.

Study Type: Genome-first cohort study

Key Question: Does the prevalence and clinical impact of familial hypercholesterolemia variants differ between African and European ancestry populations?

Key Findings:

• Pathogenic FH variant prevalence was similar between African (1 in 306) and European (1 in 273) ancestry groups
• African ancestry individuals had 1.61-fold higher odds of having variants of unknown significance (VUS) and 20.81 mg/dL greater LDL-C elevation with pathogenic variants
• VUS conferred myocardial infarction risk equivalent to pathogenic variants in African ancestry individuals (OR 1.91) but not in European ancestry individuals

Clinical Relevance: Current FH diagnostic criteria may systematically underdiagnose African ancestry patients in the UK, as variants classified as "unknown significance" appear clinically significant in this population.

Limitations: Study limited to US populations and genetic ancestry classification may not fully capture the complexity of African diaspora genetics relevant to UK practice.